503B Outsourcing Facility

Section 503B, created by the Drug Quality and Security Act of 2013 after the New England Compounding Center meningitis outbreak, invented a category that had not existed: a compounder that voluntarily registers with FDA as an outsourcing facility. In exchange it may compound without a prescription for an identified patient, which is what permits office stock, and it must comply with current good manufacturing practice, submit product reports twice a year, report adverse events and accept FDA inspection.

The bulk substance rule is tighter than the 503A version. An outsourcing facility may use a bulk drug substance only if it appears on FDA's list of substances for which there is a clinical need, or if the drug is on the shortage list; there is no monograph route. That clinical need list is built nomination by nomination and FDA has removed entries as well as added them, so whether a given peptide can lawfully be used at a 503B is a question for the current list rather than a settled fact.

The distinction matters when judging a supply chain. A 503B product is made under CGMP, in a facility FDA can and does inspect, with sterility and potency testing on the batch, which places it closer to a manufacturer than to a corner pharmacy. It is still not an approved drug: no application was reviewed, no formulation was assessed, and inspection findings at registered facilities are frequently substantial.

The error is treating the 503B label as a stamp of approval, or as evidence that a specific product was made under it. Registration lists the facility, not each preparation, and a clinic naming a 503B says nothing about which lot reached the patient. Inspection observations and recalls at outsourcing facilities are published, and are worth reading before treating the category as equivalent to a licensed manufacturer.